Edgar Filing: bluebird bio, Inc. - Form 4

bluebird bio, Inc. Form 4 October 19, 2015 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).									
(Print or Type	Responses)								
1. Name and A Davidson I	Address of Reporting Person <u>*</u> David	2. Issuer Name ar Symbol bluebird bio, Ind			8	5. Relationship of l Issuer (Check	Reporting Pers		
(Last) C/O BLUE SECOND S	3. Date of Earliest 7 (Month/Day/Year) 10/15/2015	5/2015 —				Director 10% Owner X Officer (give title Other (specify below) below) Chief Medical Officer			
CAMBRID	4. If Amendment, I Filed(Month/Day/Ye	-	nal	-	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)	any	emed 3. on Date, if Transacti Code /Day/Year) (Instr. 8)		ities A osed of , 4 and (A) or	cquired (A)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	10/15/2015	М	2,000	А	\$ 2.09	2,000	D		
Common Stock	10/15/2015	S <u>(1)</u>	575	D	\$ 78.9879 (2)	1,425	D		
Common Stock	10/15/2015	S <u>(1)</u>	1,329	D	\$ 79.9216 <u>(3)</u>	96	D		
Common Stock	10/15/2015	S <u>(1)</u>	96	D	\$ 80.89 (4)	0	D		

Edgar Filing: bluebird bio, Inc. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. I Dei Sec (Ini
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 2.09	10/15/2015		М	2,000	(5)	04/13/2022	Common Stock	2,000	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Davidson David C/O BLUEBIRD BIO, INC. 150 SECOND STREET CAMBRIDGE, MA 02141			Chief Medical Officer				
Signatures							

/s/Jason F. Cole, Attorney-in-Fact

10/19/2015

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 14, 2015.

The range of prices for the transaction reported on this line was \$78.51 to \$79.50. The average weighted price was \$78.9879. The

(2) reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Edgar Filing: bluebird bio, Inc. - Form 4

The range of prices for the transaction reported on this line was \$79.52 to \$80.43. The average weighted price was \$79.9216. The
(3) reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The range of prices for the transaction reported on this line was \$80.84 to \$80.99. The average weighted price was \$80.89. The reporting
 (4) person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

(5) This option vests over a four-year period, at a rate of twenty-five percent (25%) on February 13, 2013 and in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.